|
|
||||||||
Massachusetts General Hospital, Boston, Massachusetts
Correspondence: For reprints contact: Edgar Haber, MD, Cardiac Unit, Mass. General Hosp., Boston, MA 02114.
ABSTRACT
We have developed a method of labeling biologically active labile macromolecules, such as human fibrinogen (HF) and anticardiac-myosin Fab (AM-Fab), with Tc-99m at neutral pH. This method uses dithionite reduction of pertechnetate and subsequent labeling, to test the method with acid-labile macromolecules. Complexes of diethylene triamine pentaacetic acid with macromolecules such as human fibrinogen (D-HF) and anticardiac-myosin Fab (D-AM-Fab) were labeled and utilized in in vitro and in vivo studies. In biodistribution studies, the Tc-99m D-HF had a two-component blood clearance (half-times 1 hr and 15 hr) and was 8088% coagulable. The Tc-99m AM-Fab retained its immunoreactivity as tested by affinity chromatography; also during in vivo localization in experimental myocardial infarction. This labeling technique provides an easy and efficient approach to the Tc-99m labeling of other biologically active and acid-labile macromolecules.
This article has been cited by other articles:
![]() |
M. Breuer, A. Schutz, M. Engelhardt, C. Hammer, B.M. Kemkes, and M. Breuer Scintigraphy and Immunohistology of Antimyosin-Fab During Graft Rejection Angiology, July 1, 1999; 50(7): 563 - 571. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |